Last10K.com

Rexahn Pharmaceuticals, Inc. (RNN) SEC Filing 10-Q Quarterly report for the period ending Saturday, September 30, 2017

Rexahn Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1861796 Ticker: RNN
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2017
Nov. 03, 2017
Document And Entity Information [Abstract]  
Document Type10-Q 
Amendment Flagfalse 
Document Period End DateSep. 30, 2017 
Entity Registrant NameREXAHN PHARMACEUTICALS, INC. 
Entity Central Index Key0001228627 
Current Fiscal Year End Date--12-31 
Entity Filer CategoryAccelerated Filer 
Document Fiscal Year Focus2017 
Document Fiscal Period FocusQ3 
Trading Symbolrnn 
Entity Common Stock, Shares Outstanding 31,725,114

View differences made from one quarter to another to evaluate Rexahn Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Rexahn Pharmaceuticals, Inc..

Continue

Assess how Rexahn Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Rexahn Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Balance Sheet
Condensed Balance Sheet (parenthetical)
Condensed Statement Of Cash Flows
Condensed Statement Of Comprehensive Loss
Condensed Statement Of Operations
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (details)
Accounts Payable And Accrued Expenses (tables)
Commitments And Contingencies
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (schedule Of Future Rental Payments) (details)
Commitments And Contingencies (tables)
Common Stock
Common Stock (narrative) (details)
Common Stock (summary Of Allocation Of Proceeds From Offering) (details)
Common Stock (tables)
Deferred Research And Development Arrangement
Deferred Research And Development Arrangement (details)
Equipment, Net
Equipment, Net (details)
Equipment, Net (tables)
Fair Value Measurements
Fair Value Measurements (reconciliation Of Changes In The Fair Value Of Liabilities) (details)
Fair Value Measurements (schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis) (details)
Fair Value Measurements (tables)
Income Taxes
Income Taxes (narrative) (details)
Income Taxes (schedule Of Deferred Tax Assets And Valuation Allowance) (details)
Income Taxes (tables)
Marketable Securities
Marketable Securities (narrative) (details)
Marketable Securities (schedule Of Cost And Fair Value By Contractual Maturity) (details)
Marketable Securities (schedule Of Cost And Fair Value Of Marketable Securities) (details)
Marketable Securities (tables)
Net Loss Per Common Share
Net Loss Per Common Share (details)
Operations And Organization
Operations And Organization (details)
Operations And Organization (policies)
Other Liabilities
Other Liabilities (narrative) (details)
Other Liabilities (schedule Of Deferred Lease Incentive) (details)
Other Liabilities (tables)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (details)
Prepaid Expenses And Other Current Assets (tables)
Recent Accounting Pronouncements Affecting The Company
Recent Accounting Pronouncements Affecting The Company (policies)
Stock-based Compensation
Stock-based Compensation (narrative) (details)
Stock-based Compensation (schedule Of Assumptions Made In Calculating The Fair Value Of Options) (details)
Stock-based Compensation (summary Of Rsu Activity) (details)
Stock-based Compensation (summary Of Stock Compensation Expense) (details)
Stock-based Compensation (summary Of Stock Options Outstanding) (details)
Stock-based Compensation (summary Of Unvested Shares) (details)
Stock-based Compensation (tables)
Subsequent Events
Subsequent Events (details)
Warrants
Warrants (narrative) (details)
Warrants (schedule Of Assumptions Used In Calculating Fair Value Of Warrants) (details)
Warrants (schedule Of Fair Value Of Warrants Issued) (details)
Warrants (schedule Of Unrealized Gain/(loss) On Fair Value Of Warrants) (details)
Warrants (summary Of Changes In Warrants Outstanding During The Period) (details)
Warrants (summary Of Shares Indexed To The Warrants) (details)
Warrants (tables)

Material Contracts, Statements, Certifications & more

Rexahn Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Ticker: RNN
CIK: 1228627
Form Type: 10-Q Quarterly Report
Accession Number: 0001140361-17-040967
Submitted to the SEC: Fri Nov 03 2017 4:16:34 PM EST
Accepted by the SEC: Fri Nov 03 2017
Period: Saturday, September 30, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/rnn/0001140361-17-040967.htm